Brief: PCI Biotech: Positive opinion for Orphan Drug Designation for fimaporfin

PCI Biotech Holding ASA

25/07/2016 19:47

July 26 (Reuters) - PCI Biotech ASA  PCIB.OL : 
    * Said on Monday it had received positive opinion from European Medicine Agency's (EMA) 
Committee for Orphan Medicinal Products (COMP) for fimaporfin for treatment of 
cholangiocarcinoma (bile duct cancer) 
    * COMP's positive opinion is subject to decision by the European Commission for Orphan 
Designation 
 
     
 Source text for Eikon:  urn:newsml:reuters.com:*:nHUGbqgkbZ 
     
 Further company coverage:  PCIB.OL   
    
 
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))